ProPhase Labs (NASDAQ:PRPH) Stock Price Passes Below 200 Day Moving Average – Here’s What Happened

ProPhase Labs, Inc. (NASDAQ:PRPH) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.86 and traded as low as $0.0720. ProPhase Labs shares last traded at $0.0751, with a volume of 37,941 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of ProPhase Labs to a “hold” rating in a research report on Saturday, December 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

ProPhase Labs Stock Performance

The company has a debt-to-equity ratio of 0.14, a current ratio of 0.14 and a quick ratio of 0.14. The company has a fifty day moving average of $0.15 and a two-hundred day moving average of $1.83. The stock has a market capitalization of $444,423.60, a P/E ratio of -0.02 and a beta of -0.52.

Institutional Trading of ProPhase Labs

Institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in shares of ProPhase Labs in the 2nd quarter valued at about $40,000. Apollon Wealth Management LLC acquired a new position in ProPhase Labs in the third quarter valued at approximately $84,000. Accretive Wealth Partners LLC acquired a new position in ProPhase Labs in the third quarter valued at approximately $114,000. Finally, Susquehanna International Group LLP grew its holdings in shares of ProPhase Labs by 290.1% during the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after purchasing an additional 295,899 shares during the last quarter. 9.45% of the stock is owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.